Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Adaptive Biotechnologies Corp (NASDAQ:ADPT) stock (market cap: $1.23 billion) has surged to a 52-week high, with shares hitting the $8.33 mark, significantly above its 52-week low of $2.28. This milestone reflects a significant turnaround for the company, which has seen an impressive 110.41% change over the past year. According to InvestingPro, the company maintains strong liquidity with a current ratio of 2.89 and achieved 5.1% revenue growth. Investors have shown renewed confidence in Adaptive Biotechnologies’ potential, as the company continues to make strides in the biotech industry. The 52-week high serves as a testament to the company’s resilience and the growing investor optimism surrounding its future prospects. InvestingPro analysis reveals 12 additional investment tips and comprehensive financial metrics available for subscribers looking to make informed investment decisions.
In other recent news, Adeptus Biotechnologies Corp. has seen a price target increase to $12 by Scotiabank (TSX:BNS), following a strong finish to the fiscal year 2024. This adjustment comes after the company’s robust growth, with a revenue guidance for 2025 projecting a 30% year-over-year increase, aiming for revenues between $175 and $185 million. This forecast is attributed to factors such as increased average selling prices for clonoSEQ, expansion of blood-based testing, and strategic commercial partnerships.
In addition, Adeptus plans to increase operating expenses by a low single-digit percentage, capitalizing on lab efficiencies and a transition to the NovaSeq X platform. The company’s disciplined approach is projected to reduce total cash burn by roughly 28%, estimating it to fall between $60 and $70 million. Adeptus ended 2024 with a reported cash reserve of $256 million.
Adeptus is aiming for MRD adjusted EBITDA profitability in the second half of 2025 and cash flow breakeven in the first half of 2026. The increased estimates and price target from Scotiabank reflect the significant growth potential of Adeptus’s MRD business. Scotiabank’s analyst maintained a Sector Outperform rating, highlighting confidence in the company’s growth trajectory.
In a parallel development, Adaptive Biotechnologies Corporation reported Q4 results that surpassed analyst expectations on revenue and showed a narrower loss than anticipated. The company’s MRD business, contributing 85% of Q4 revenue, grew 31% YoY to $40.1 million. For 2025, Adaptive projects MRD business revenue between $175 million and $185 million. The company ended 2024 with $256 million in cash and marketable securities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.